Castle Biosciences Inc (CSTL) Stock Price & Analysis

Castle Biosciences Inc (CSTL) rose 4.77% to USD 21.08 as of June 10, 2026 at 03:29 UTC, according to Nexqual real-time market data.

CSTL last closed at USD 20.12; the session ranged USD 20.24–21.09 on volume of 253,553 shares. Market capitalization is $639.36M, with a 52-week range of USD 14.59–44.28 (NGM). Source: Nexqual, June 10, 2026 at 03:29 UTC.

Key Statistics (as of June 10, 2026 at 03:29 UTC)

Technical Analysis (CSTL)

Nexqual's technical model rates CSTL "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:29 UTC.

Analyst Ratings (CSTL)

Wall Street analysts rate CSTL "Strong Buy" based on 8 analysts, with a mean price target of USD 44 (range USD 35–52), per Nexqual as of June 10, 2026 at 03:29 UTC.

Earnings (CSTL)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:29 UTC.

Financials & Fundamentals (CSTL)

Source: Nexqual, June 10, 2026 at 03:29 UTC.

Financial Health Score (CSTL)

Nexqual rates Castle Biosciences Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:29 UTC.

Ownership (CSTL)

Source: Nexqual, June 10, 2026 at 03:29 UTC.

Leadership (CSTL)

Castle Biosciences Inc is led by Derek J. Maetzold (age 63), Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 03:29 UTC.

Major Backers & Investors (CSTL)

Notable institutional backers of Castle Biosciences Inc include RTW Investments LP, Principal Financial Group, Inc., Portolan Capital Management, LLC, according to Nexqual as of June 10, 2026 at 03:29 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:29 UTC.

From Castle Biosciences Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary tests, which were first marketed prior to May 6, 2024, remain approved by and under the oversight of the NYSDOH, and we continue to believe that changes in FDA's regulatory approach to LDTs will have no material impact on our existing test offerings.
• Medical Device Regulatory Framework Although we currently market our proprietary testing products as LDTs, which are currently subject to enforcement discretion, we could be subject to FDA compliance obligations in the future.
• DecisionDx-Melanoma DecisionDx-Melanoma is our proprietary risk stratification gene expression profile ("GEP") test designed to predict the likelihood of a positive sentinel lymph node and the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma ("CM"), a deadly skin cancer.
• DecisionDx-SCC DecisionDx‑SCC is our proprietary GEP test designed for use in patients with cutaneous squamous cell carcinoma ("SCC"), the second most common form of skin cancer, with one or more risk factors (also referred to as "high-risk" SCC).

Partnerships

• If these suppliers can no longer provide us with the materials we need to perform our test services, they do not meet our quality specifications, or we cannot obtain acceptable substitute materials, our business would likely be negatively affected. 12 Table of Contents License Agreement with The Washington University In November 2009, we entered into a license agreement (the "License Agreement") with The Washington University in St.
• In June 2025, we entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") to develop and commercialize diagnostic tests for dermatologic diseases, beginning with atopic dermatitis.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:29 UTC. This page is informational and not investment advice.